Literature DB >> 8534767

Correlation between immunophenotypic diversity and clinical features in B-cell lymphoblastic lymphoma.

K Shibata1, Y Shimamoto, H Yamada, M Miyahara, N Fukushima, H Yano.   

Abstract

Lymphoblastic lymphoma (LBL) is a highly malignant subtype of non-Hodgkin's lymphoma (NHL) and generally carries a T-cell phenotype with mediastinum or central nervous system (CNS) involvement. However, only a small proportion of LBL exhibit a B-cell phenotype (B-LBL), and these frequently present at the head and neck without mediastinum or CNS involvement. Three immunological subgroups may exist. The most predominant CD10-positive pre-B-cell type, corresponding to a precursor B-cell neoplasm, frequently involves the head and neck. The second, CD10-negative or mature B-cell type, defined by the absence of CD10 or presence of surface membrane immunoglobulins combined with expression of CD19 or CD20, often involves the mediastinum. The final group is a CD5-positive B-cell type corresponding to a blastic variant of mantle cell lymphoma (MCL). Its clinical course is less aggressive, patients are often older, and nodal lesions are more frequent than extranodal involvement. Thus, B-LBL is immunologically diverse, but its biological behavior correlates with the immunophenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534767     DOI: 10.1007/bf01697988

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  21 in total

Review 1.  Lymphoblastic lymphoma.

Authors:  V J Picozzi; C N Coleman
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929

2.  Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia.

Authors:  L M Weiss; J M Bindl; V J Picozzi; M P Link; R A Warnke
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

3.  Characteristic clinicopathologic features of adult B-cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation origin.

Authors:  A L Cheng; I J Su; H F Tien; C C Wang; Y C Chen; C H Wang
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

4.  Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior.

Authors:  K Sheibani; B N Nathwani; C D Winberg; J S Burke; W G Swartz; D Blayney; S van de Velde; L R Hill; H Rappaport
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

5.  Lymphoblastic lymphoma with the phenotype of common acute lymphoblastic leukemia.

Authors:  M J Borowitz; B P Croker; R S Metzgar
Journal:  Am J Clin Pathol       Date:  1983-03       Impact factor: 2.493

6.  New cell line from hairy-cell leukaemia producing interleukin-6 after Epstein-Barr virus immortalization.

Authors:  T Tokioka; Y Shimamoto; F Nagumo; J Tadano; M Yamaguchi
Journal:  Acta Haematol       Date:  1994       Impact factor: 2.195

7.  B-cell differentiation pattern of cutaneous lymphomas in infancy and childhood.

Authors:  E R Grümayer; R L Ladenstein; I Slavc; C Urban; T Radaszkiewicz; P Bettelheim; H Gadner
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

8.  Mediastinal lymphoblastic lymphoma with an immature B-cell immunophenotype.

Authors:  C A Sander; E S Jaffe; F C Gebhardt; T Yano; L J Medeiros
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

9.  Mantle cell lymphoma with the features of mucosa-associated lymphoid tissue (MALT) lymphoma in an HTLV-I-seropositive patient.

Authors:  K Shibata; Y Shimamoto; S Nakano; M Miyahara; H Nakano; M Yamaguchi
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.